A model-based analysis of the health impacts of COVID-19 disruptions to primary cervical screening by time since last screen for current and future disruptions

Acknowledgements Emily A Burger receives salary support from the Norwegian Cancer Society (#198073), Megan A Smith receives salary support from the National Health and Medical Research Council, Australia (APP1159491) and Cancer Institute NSW (ECF181561). James O’Mahony is funded by Ireland’s Health Research Board (EIA2017054). Matejka Rebolj receives support from Public Health England, which provided funding for evaluation of various PHE projects; member of various PHE advisory groups for cervical screening; attended meetings with various HPV assay manufacturers; fee for lecture in the last four years from Hologic, paid to employer. Funding Funder Grant reference number Author National Cancer Institute U01CA199334 Jane J Kim Karen Canfell Inge MCM de Kok Cancer Research UK C8162/A27047 Matejka Rebolj Alejandra Castanon Norwegian Cancer Society #198073 Emily A Burger National Health and Medical Research Council, Australia APP1159491 Megan A Smith Cancer Institute NSW ECF181561 Megan A Smith Ireland’s Health Research Board EIA2017054 James F O'Mahony Public Health England Matejka Rebolj The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication. The contents are solely the responsibility of the authors and do not necessarily represent the officialPeer reviewedPublisher PD